Patents by Inventor Dieter Wiedenmayer

Dieter Wiedenmayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
    Patent number: 11992494
    Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: May 28, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Ferenc Kontes, Christofer Siegfried Tautermann, Dieter Wiedenmayer, Marina Kristina Willwacher
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240076286
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 7, 2024
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240002363
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 4, 2024
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 11851418
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: December 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Maude Giroud, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20230355638
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: July 14, 2023
    Publication date: November 9, 2023
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
    Patent number: 11766443
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Marina Kristina Willwacher, Juergen Prestle, Ferenc Kontes, Leo Thomas, Christofer Siegfried Tautermann, Dieter Wiedenmayer
  • Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 11760745
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 19, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Maude Giroud, Elke Langkopf, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20230190763
    Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: December 19, 2022
    Publication date: June 22, 2023
    Inventors: Matthias ECKHARDT, Ferenc KONTES, Christofer Siegfried TAUTERMANN, Dieter Wiedenmayer, Marina Kristina WILLWACHER
  • Imidazopyrazine Derivatives and the Use Thereof as Medicament
    Publication number: 20220306637
    Abstract: The present invention relates to novel imidazopyrazines of general formula A, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 29, 2022
    Inventors: Riccardo GIOVANNINI, Dieter WIEDENMAYER
  • Purine derivatives and the use thereof as medicament
    Patent number: 11376258
    Abstract: The present invention relates to novel purines of general formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: July 5, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Dieter Wiedenmayer
  • Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists
    Publication number: 20220160725
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 26, 2022
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    Publication number: 20210393644
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 23, 2021
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210387963
    Abstract: Disclosed are phenyltetrazole derivatives of formula (I), wherein A, R1, R2, X, R?, R?, and n are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the phenyltetrazole derivatives for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: October 7, 2019
    Publication date: December 16, 2021
    Inventors: Dieter WIEDENMAYER, Andreas GOLLNER, Iain LINGARD, Holger WAGNER
  • Purine derivatives and the use thereof as medicament
    Publication number: 20210369723
    Abstract: The present invention relates to novel purines of general formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 2, 2021
    Inventors: Riccardo GIOVANNINI, Dieter WIEDENMAYER
  • 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11155539
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: October 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210292301
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 23, 2021
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210276976
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Inventors: Matthias ECKHARDT, Maude GIROUD, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11104670
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Imidazopyridine derivatives and the use thereof as medicament
    Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer